Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease

Authors

Institutions

Publication Details

Journal
Journal of Crohn s and Colitis
Published
2025-11-19
DOI
https://doi.org/10.1093/ecco-jcc/jjaf198
Citations
1
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
1.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease

Sharanya Ford, Bettina Wick-Urban, Remo Panaccione, Kendall Beck et al.
1 citations
Journal of Crohn s and Colitis
Inflammatory Bowel Disease
1.82
article

Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease

Sharanya Ford, Bettina Wick-Urban, Remo Panaccione, Kendall Beck, Javier P. Gisbert, Severine A.R.A. Vermeire, Valencia P. Remple, Elena Dubcenco, Laurent Peyrin‐Biroulet, Silvio Danese, María Chaparro, Edward V. Loftus, Benjamin Duncan, Justin Klaff, Grace Naling, Yibo Wang, Namita Joshi, Jean–Frédéric Colombel, Smitha Suravaram
article en
1 citations

Abstract

No abstract available for this paper.
Journal of Crohn s and ColitisVol. 20(1)
Mayo Clinic (US), University of Calgary (CA), University of California, San Francisco (US), Ludwigshafen University of Business and Society (DE), McGill University Health Centre (CA), AbbVie (United States) (US), Mayo Clinic in Arizona (US), AbbVie (Germany) (DE), Klinikum Ludwigshafen (DE), Hospital Universitario de La Princesa (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), IRCCS Ospedale San Raffaele (IT), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Universidad Autónoma de Madrid (ES), Université de Lorraine (FR), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)
Openalex Percentile: Top 11%
Inflammatory Bowel Disease
1.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.